$2.3T
Total marketcap
$347.27B
Total volume
BTC 55.67%     ETH 9.33%
Dominance

AstraZeneca PLC AZNCF Stock

$187.45   0.000000%
Add to favorites
Market Cap
$290.60B
LOW - HIGH [24H]
$0.00 - $0.00
VOLUME [24H]
$0.00
P/E Ratio
0
Earnings per share
$0.00
ISIN
GB0009895292
Price   Prediction

AstraZeneca PLC Price Chart

Sorry, that's all we've gotfor now...

AstraZeneca PLC AZNCF Financial and Trading Overview

AstraZeneca PLC stock price 187.45 USD
Previous Close 184.32 USD
Open 178.29 USD
Bid 176.31 USD x 10100
Ask 192.79 USD x 10000
Day's Range 178.29 - 178.29 USD
52 Week Range 122.26 - 195 USD
Volume 200 USD
Avg. Volume 161.84K USD
Market Cap 290.6B USD
Beta (5Y Monthly) 0.192
PE Ratio (TTM) 31.086233
EPS (TTM) 0 USD
Forward Dividend & Yield 3.21 (1.70%)
Ex-Dividend Date August 7, 2025
1y Target Est 104 USD

AZNCF Valuation Measures

Enterprise Value 316.79B USD
Trailing P/E 31.086233
Forward P/E 37.045456
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 4.999409
Price/Book (mrq) 6.335767
Enterprise Value/Revenue 5.45
Enterprise Value/EBITDA 15.517

Trading Information

AstraZeneca PLC Stock Price History

Beta (5Y Monthly) 0.192
52-Week Change 23.72%
S&P500 52-Week Change 32.69%
52 Week High 195 USD
52 Week Low 122.26 USD
50-Day Moving Average 183.86 USD
200-Day Moving Average 161.39 USD

AZNCF Share Statistics

Avg. Volume (3 month) 161.84K USD
Avg. Daily Volume (10-Days) 978.97K USD
Shares Outstanding 1.55B
Float 1.54B
Short Ratio N/A
% Held by Insiders 0.027%
% Held by Institutions 56.02%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 3.13
Trailing Annual Dividend Yield 1.69%
5 Year Average Dividend Yield 217.00%
Payout Ratio 0.5205
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2024
Most Recent Quarter (mrq) September 30, 2025
Next Fiscal Year End December 31, 2025

Profitability

Profit Margin 16.17%
Operating Margin (ttm) 24.10%
Gross Margin 83.25%
EBITDA Margin 35.12%

Management Effectiveness

Return on Assets (ttm) 9.06%
Return on Equity (ttm) 21.67%

Income Statement

Revenue (ttm) 58.13B USD
Revenue Per Share (ttm) 37.5 USD
Quarterly Revenue Growth (yoy) 12.00%
Gross Profit (ttm) 48.4B USD
EBITDA 20.42B USD
Net Income Avi to Common (ttm) 9.4B USD
Diluted EPS (ttm) 6.03
Quarterly Earnings Growth (yoy) 77.29%

Balance Sheet

Total Cash (mrq) 8.18B USD
Total Cash Per Share (mrq) 5.28 USD
Total Debt (mrq) 32.66B USD
Total Debt/Equity (mrq) 71.05 USD
Current Ratio (mrq) 0.879
Book Value Per Share (mrq) 29.586

Cash Flow Statement

Operating Cash Flow (ttm) 15.14B USD
Levered Free Cash Flow (ttm) 9.98B USD

Profile of AstraZeneca PLC

Country United States
State N/A
City Cambridge
Address 1 Francis Crick Avenue
ZIP CB2 0AA
Phone 44 20 3749 5000
Website https://www.astrazeneca.com
Industry Drug Manufacturers - General
Sector(s) Healthcare
Full Time Employees 94300

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple next-generation therapies for obesity and type 2 diabetes; and collaboration Revna Biosciences for lung cancer treatment. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Q&A For AstraZeneca PLC Stock

What is a current AZNCF stock price?

AstraZeneca PLC AZNCF stock price today per share is 187.45 USD.

How to purchase AstraZeneca PLC stock?

You can buy AZNCF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for AstraZeneca PLC?

The stock symbol or ticker of AstraZeneca PLC is AZNCF.

Which industry does the AstraZeneca PLC company belong to?

The AstraZeneca PLC industry is Drug Manufacturers - General.

How many shares does AstraZeneca PLC have in circulation?

The max supply of AstraZeneca PLC shares is 1.55B.

What is AstraZeneca PLC Price to Earnings Ratio (PE Ratio)?

AstraZeneca PLC PE Ratio is 0.00000000 now.

What was AstraZeneca PLC earnings per share over the trailing 12 months (TTM)?

AstraZeneca PLC EPS is 0 USD over the trailing 12 months.

Which sector does the AstraZeneca PLC company belong to?

The AstraZeneca PLC sector is Healthcare.

Select currency